Overexpression of TBX3 transcription factor as a potential diagnostic marker for breast cancer

Aliwaini,Saeb; Lubbad,Abdel  Monem; Shourfa,Ahmed; Hamada,Hosam  A.A.; Ayesh,Basim; Abu Tayem,Husam  Eddeen M.; Abu Mustafa,Ayman; Abu Rouk,Fayek; Redwan,Moen  M.; Al‑Najjar,Mohamed

doi:10.3892/mco.2018.1761

Overexpression of TBX3 transcription factor as a potential diagnostic marker for breast cancer

Authors:
- Saeb Aliwaini
- Abdel Monem Lubbad
- Ahmed Shourfa
- Hosam A.A. Hamada
- Basim Ayesh
- Husam Eddeen M. Abu Tayem
- Ayman Abu Mustafa
- Fayek Abu Rouk
- Moen M. Redwan
- Mohamed Al‑Najjar
View Affiliations

Affiliations: Department of Biological Sciences and Biotechnology, Faculty of Sciences, Islamic University of Gaza, 108 Gaza, Palestine, Department of Pathology, Faculty of Medicine, Islamic University of Gaza, 108 Gaza, Palestine , Department of Oncology, European Gaza Hospital, 7049 Gaza, Palestine, Department of Pathology, Alshefa Hospital, 1016 Gaza, Palestine, Department of Laboratory Medical Sciences, Alaqsa University, 4051 Gaza, Palestine, Nursing Department, Palestine College of Nursing, 7049 Gaza, Palestine
Published online on: November 9, 2018 https://doi.org/10.3892/mco.2018.1761
Pages: 105-112
Copyright: © Aliwaini et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The T‑box 3 (TBX3) transcription factor has been shown to serve multiple roles in normal development. Recent findings have revealed that TBX3 is overexpressed in different types of carcinomas, including breast, cervical, ovarian, melanoma, pancreatic, lung, liver, bladder, head and neck. Therefore, the present study investigated the significance of TBX3 as a diagnostic marker of breast cancer. To achieve this aim, breast cancer samples and their adjacent normal tissues were collected from 51 breast cancer patients from the European Gaza hospital during 2015‑2016. Sections from each sample were immune‑stained by anti‑TBX3 and suitable secondary and tertiary antibodies. TBX3 levels were evaluated in cancerous and normal samples. Clinicopathological data for each patient were documented. The correlation between TBX3 levels and the clinicopathological parameters were statistically tested. The results revealed that TBX3 is significantly overexpressed in breast cancer tissues when compared with normal tissues. Furthermore, TBX3 was mainly a cytoplasmic protein in normal and breast cancer tissues. Notably, TBX3 levels exhibited a sensitivity of 78.4%, specificity of 79.6%, accuracy of 79% and area under the curve of 0.791 (0.700‑0.882) at a cut‑off value=9 as breast cancer marker. However, no significant associations were observed between TBX3 levels and other breast cancer markers including oestrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, cancer antigen 15‑3 and breast cancer stages. Altogether, these results suggested that TBX3 overexpression may be a potential biomarker for breast cancer.

View Figures

View References

1	Willmer T, Peres J, Mowla S, Abrahams A and Prince S: The T-Box factor TBX3 is important in S-phase and is regulated by c-Myc and cyclin A-CDK2. Cell Cycle. 14:3173–3183. 2015. View Article : Google Scholar : PubMed/NCBI
2	Cheng HD, Lui YM and Freimanis RI: A novel approach to microcalcification detection using fuzzy logic technique. IEEE Trans Med Imaging. 17:442–450. 1998. View Article : Google Scholar : PubMed/NCBI
3	American Cancer Society: Cancer Treatment and Survivorship Facts and Figures 2012–2013. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-surviorship-facts-and-figures/cancer-treatment-and-survivorship-facts-and-figures-2012-2013.pdfJanuary 1–2012
4	Ashkenazi A: Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 19:325–331. 2008. View Article : Google Scholar : PubMed/NCBI
5	Naiche LA, Harrelson Z, Kelly RG and Papaioannou VE: T-box genes in vertebrate development. Annu Rev Genet. 39:219–239. 2005. View Article : Google Scholar : PubMed/NCBI
6	Peres J and Prince S: The T-box transcription factor, TBX3, is sufficient to promote melanoma formation and invasion. Mol Cancer. 12:1172013. View Article : Google Scholar : PubMed/NCBI
7	Bilican B and Goding CR: Cell cycle regulation of the T-box transcription factor tbx2. Exp Cell Res. 312:2358–2366. 2006. View Article : Google Scholar : PubMed/NCBI
8	Burgucu D, Guney K, Sahinturk D, Ozbudak IH, Ozel D, Ozbilim G and Yavuzer U: Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma. BMC Cancer. 12:4812012. View Article : Google Scholar : PubMed/NCBI
9	Demay F, Bilican B, Rodriguez M, Carreira S, Pontecorvi M, Ling Y and Goding CR: T-box factors: Targeting to chromatin and interaction with the histone H3 N-terminal tail. Pigment Cell Res. 20:279–287. 2007. View Article : Google Scholar : PubMed/NCBI
10	Hoogaars WM, Barnett P, Rodriguez M, Clout DE, Moorman AF, Goding CR and Christoffels VM: TBX3 and its splice variant TBX3 + exon 2a are functionally similar. Pigment Cell Melanoma Res. 21:379–387. 2008. View Article : Google Scholar : PubMed/NCBI
11	Humtsoe JO, Koya E, Pham E, Aramoto T, Zuo J, Ishikawa T and Kramer RH: Transcriptional profiling identifies upregulated genes following induction of epithelial-mesenchymal transition in squamous carcinoma cells. Exp Cell Res. 318:379–390. 2012. View Article : Google Scholar : PubMed/NCBI
12	Peres J, Davis E, Mowla S, Bennett DC, Li JA, Wansleben S and Prince S: The highly homologous T-Box transcription factors, TBX2 and TBX3, have distinct roles in the oncogenic process. Genes Cancer. 1:272–282. 2010. View Article : Google Scholar : PubMed/NCBI
13	Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, et al: Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 64:5270–5282. 2004. View Article : Google Scholar : PubMed/NCBI
14	Peres J, Mowla S and Prince S: The T-box transcription factor, TBX3, is a key substrate of AKT3 in melanomagenesis. Oncotarget. 6:1821–1833. 2015. View Article : Google Scholar : PubMed/NCBI
15	Douglas NC and Papaioannou VE: The T-box transcription factors TBX2 and TBX3 in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia. 18:143–147. 2013. View Article : Google Scholar : PubMed/NCBI
16	Wu G, Sinclair C, Hinson S, Ingle JN, Roche PC and Couch FJ: Structural analysis of the 17q22-23 amplicon identifies several independent targets of amplification in breast cancer cell lines and tumors. Cancer Res. 61:4951–4955. 2001.PubMed/NCBI
17	Jacobs JJ, Keblusek P, Robanus-Maandag E, Kristel P, Lingbeek M, Nederlof PM, van Welsem T, van de Vijver MJ, Koh EY, Daley GQ, et al: Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19 (ARF)) and is amplified in a subset of human breast cancers. Nat Genet. 26:291–299. 2000. View Article : Google Scholar : PubMed/NCBI
18	Redmond KL, Crawford NT, Farmer H, D'Costa ZC, O'Brien GJ, Buckley NE, Kennedy RD, Johnston PG, Harkin DP and Mullan PB: T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells. Oncogene. 29:3252–3262. 2010. View Article : Google Scholar : PubMed/NCBI
19	Yu J, Ma X, Cheung KF, Li X, Tian L, Wang S, Wu CW, Wu WK, He M, Wang M, et al: Epigenetic inactivation of T-box transcription factor 5, a novel tumor suppressor gene, is associated with colon cancer. Oncogene. 29:6464–6474. 2010. View Article : Google Scholar : PubMed/NCBI
20	Wansleben S, Davis E, Peres J and Prince S: A novel role for the anti-senescence factor TBX2 in DNA repair and cisplatin resistance. Cell Death Dis. 4:e8462013. View Article : Google Scholar : PubMed/NCBI
21	Yarosh W, Barrientos T, Esmailpour T, Lin L, Carpenter PM, Osann K, Anton-Culver H and Huang T: TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases. Cancer Res. 68:693–699. 2008. View Article : Google Scholar : PubMed/NCBI
22	Lomnytska M, Dubrovska A, Hellman U, Volodko N and Souchelnytskyi S: Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients. Int J Cancer. 118:412–421. 2006. View Article : Google Scholar : PubMed/NCBI
23	Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K and Walker R: Immunohistochemical detection of steroid receptors in breast cancer: A working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol. 53:634–635. 2000. View Article : Google Scholar : PubMed/NCBI
24	Sasaki T, Ryo A, Uemura H, Ishiguro H, Inayama Y, Yamanaka S, Kubota Y, Nagashima Y, Harada M and Aoki I: An immunohistochemical scoring system of prolyl isomerase Pin1 for predicting relapse of prostate carcinoma after radical prostatectomy. Pathol Res Pract. 202:357–364. 2006. View Article : Google Scholar : PubMed/NCBI
25	Fan W, Huang X, Chen C, Gray J and Huang T: TBX3 and its isoform TBX3+2a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines. Cancer Res. 64:5132–5139. 2004. View Article : Google Scholar : PubMed/NCBI
26	Sasaki K, Bastacky SI, Zynger DL and Parwani AV: Use of immunohistochemical markers to confirm the presence of vas deferens in vasectomy specimens. Am J Clin Pathol. 132:893–898. 2009. View Article : Google Scholar : PubMed/NCBI
27	Li X, Gao H, Chen Z, Zhang L, Zhu X, Wang S and Peng W: Diagnosis of breast cancer based on microcalcifications using grating-based phase contrast CT. Eur Radiol. 28:3742–3750. 2018. View Article : Google Scholar : PubMed/NCBI
28	Wu SG, He ZY, Zhou J, Sun JY, Li FY, Lin Q, Guo L and Lin HX: Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 23:88–93. 2014. View Article : Google Scholar : PubMed/NCBI
29	Di Gioia D, Blankenburg I, Nagel D, Heinemann V and Stieber P: Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3. Clin Chim Acta. 461:1–7. 2016. View Article : Google Scholar : PubMed/NCBI
30	Wang W, Xu X, Tian B, Wang Y, Du L, Sun T, Shi Y, Zhao X and Jing J: The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Clin Chim Acta. 470:51–55. 2017. View Article : Google Scholar : PubMed/NCBI
31	Willmer T, Hare S, Peres J and Prince S: The T-box transcription factor TBX3 drives proliferation by direct repression of the p21(WAF1) cyclin-dependent kinase inhibitor. Cell Div. 11:62016. View Article : Google Scholar : PubMed/NCBI
32	Horton AC, Mahadevan NR, Minguillon C, Osoegawa K, Rokhsar DS, Ruvinsky I, de Jong PJ, Logan MP and Gibson-Brown JJ: Conservation of linkage and evolution of developmental function within the Tbx2/3/4/5 subfamily of T-box genes: Implications for the origin of vertebrate limbs. Dev Genes Evol. 218:613–628. 2008. View Article : Google Scholar : PubMed/NCBI
33	Aran D, Camarda R, Odegaard J, Paik H, Oskotsky B, Krings G, Goga A, Sirota M and Butte AJ: Comprehensive analysis of normal adjacent to tumor transcriptomes. Nat Commun. 8:10772017. View Article : Google Scholar : PubMed/NCBI
34	Kunasegaran K, Ho V, Chang TH, De Silva D, Bakker ML, Christoffels VM and Pietersen AM: Transcriptional repressor Tbx3 is required for the hormone-sensing cell lineage in mammary epithelium. PLoS One. 9:e1101912014. View Article : Google Scholar : PubMed/NCBI
35	Sunwoo HH and Suresh MR: Cancer markers. In The ImmunoassayHandbook. 1. 4th edition. Elsevier Ltd.; Oxford: pp. 673–693. 2013
36	Willmer T, Cooper A, Peres J, Omar R and Prince S: The T-Box transcription factor 3 in development and cancer. Biosci Trends. 11:254–266. 2017. View Article : Google Scholar : PubMed/NCBI